⚠ Scores are AI-generated estimates for informational purposes only — not investment advice. Data may be inaccurate or outdated. Do not make financial decisions based on this site. Full legal disclaimer →
⚠ Scores are AI-generated estimates for informational purposes only — not investment advice. Data may be inaccurate or outdated. Do not make financial decisions based on this site. Full legal disclaimer →
AI Exposure Analysis
Healthcare · Large Cap · Disruption threat: LOW
Abbott integrates AI incrementally into diagnostics, continuous glucose monitoring, and cardiac devices, but AI remains an enhancing feature rather than a core revenue driver. The 2026 10-K shows continued investment in connected health and algorithm-driven diagnostics without major new AI-specific revenue disclosure warranting a score change.
Abbott Laboratories is a diversified healthcare company spanning diagnostics, medical devices, nutrition, and established pharmaceuticals. With an overall AI score of 42/100, Abbott represents a measured adopter of artificial intelligence — embedding it selectively across product lines without positioning AI as a primary commercial differentiator. The score reflects meaningful but uneven AI integration. Product AI Integration (52/100) and R&D AI Investment (48/100) are the strongest dimensions, driven by glucose prediction algorithms in its FreeStyle Libre CGM platform and machine learning applications within cardiac rhythm management devices. Internal AI Use (45/100) reflects supply chain and manufacturing optimization efforts. However, Revenue from AI (18/100) and AI Infrastructure (38/100) remain weak, indicating that AI capabilities have not yet translated into discrete, monetizable revenue streams or a robust enterprise-wide data architecture. Abbott's LOW disruption threat designation reflects its entrenched competitive position in high-switching-cost markets. Regulatory barriers, proprietary device ecosystems, and long customer relationships insulate Abbott from rapid AI-native displacement, even as competitors invest in algorithm-driven diagnostics. The primary risk is complacency. As AI-native competitors advance in continuous monitoring and diagnostic imaging, Abbott's incremental approach could erode its algorithmic differentiation over time if R&D investment intensity does not accelerate materially beyond current levels.
Full interactive analysis at RankVis.io